Beauchastel is a 198.7MW hydro power project. It is located on Rhone river/basin in Auvergne-Rhone-Alpes, France. According to GlobalData, who tracks and profiles over 170,000 power plants worldwide, the project is currently active. It has been developed in multiple phases. Post completion of construction, the project got commissioned in 1963. Buy the profile here.
Description
The project was developed by Compagnie Nationale du Rhone and is currently owned by Engie with a stake of 50%.
The project generated 1,211 GWh of electricity.
Beauchastel (Barrage de Charmes I) consists of 1 unit of bulb turbine with 0.7MW nameplate capacity.
Development status
The project got commissioned in 1963.
Contractors involved
Beauchastel (Centrale de Beauchastel) is equipped with GE Renewable Energy kaplan turbines. The phase consists of 6 turbines with 33MW nameplate capacity.
GE Renewable Energy supplied 2 electric generators for the Beauchastel (Centrale de Beauchastel). The generator capacity is 35 MVA.
For more details on Beauchastel, buy the profile here.
About Compagnie Nationale du Rhone
Compagnie Nationale du Rhone SA (CNR) a subsidiary of Engie SA, is a renewable energy company that produces electricity through renewable energy sources. The company designs and operates river and industrial facilities, small hydropower plants, mini hydropower plants, including dams, hydropower plants, wind farms, solar power plants, dikes, locks, and business parks. CNR also develops industrial and port sites, marinas, mooring points and leisure areas on the river. The company offers engineering services related to hydroelectric development and development of waterways. It operates in Condrieu, Villeneuve-les-Avignon, Bourg-les-Valence cedex, and Paris, France. CNR is headquartered in Lyon, France.
Data Insights
From
The gold standard of business intelligence.
Blending expert knowledge with cutting-edge technology, GlobalData’s unrivalled proprietary data will enable you to decode what’s happening in your market. You can make better informed decisions and gain a future-proof advantage over your competitors.